New Publication in Nature Biotechnology: Accurate detection of tumor-specific gene fusions reveals strongly immunogenic personal neo-antigens

Our research on gene fusions as individual targets for immunotherapies was published recently in Nature Biotechnology. We developed EasyFuse®, a computational pipeline to detect individual and cancer-specific gene fusions in next-generation-sequencing data from human cancer samples. We show that gene fusions, which arise from structural rearrangements in the cancer genome, are a rich source for highly immunogenic neo-antigens, which can be targeted for personal immunotherapies. Using machine learning and >1500 verification experiments, EasyFuse® archives high precision and sensitivity and outperforms previously described approaches.

Read the full article here:

The tool and source code is available here: